Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells

Journal of Controlled Release

Volumn 165, Issue 2, 2013, Pages 110-118

  Altintas, Isil ^a   Heukers, Raimond ^b   Van Der Meel, Roy ^a   Lacombe, Marie ^c   Amidi, Maryam ^a   Van Bergen En Henegouwen, Paul M P ^b   Hennink, Wim E ^a   Schiffelers, Raymond M ^a,d   Kok, Robbert J ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Linxis   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Clathrin mediated endocytosis; Coordination chemistry; Drug targeting; Engineered antibodies; Kinase inhibitor; Nanomedicine

Indexed keywords

ALBUMIN NANOPARTICLES; ANTIPROLIFERATIVE EFFECT; BIFUNCTIONAL; CLATHRIN-MEDIATED ENDOCYTOSIS; COORDINATION CHEMISTRY; CROSSLINKED; DRUG-TARGETING; EPIDERMAL GROWTH FACTOR RECEPTORS; FUNCTIONALIZED NANOPARTICLES; GLUTARALDEHYDES; HEAD-AND-NECK CANCER; IN-VITRO; KINASE INHIBITORS; METHIONINE RESIDUES; NANOMEDICINES; NON-TARGETED; PEGYLATED NANOPARTICLE; SINGLE VARIABLE; TARGETED NANOPARTICLE; TUMOR CELLS;

ALDEHYDES; AMINO ACIDS; ANTIBODIES; COORDINATION REACTIONS; MEDICAL NANOTECHNOLOGY; MOLECULAR BIOLOGY; PLATINUM; POLYETHYLENE GLYCOLS;

NANOPARTICLES;

17864; ALBUMIN; CLATHRIN; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MACROGOL; MACROGOL 3500; METHIONINE; NANOBODY; NANOPARTICLE; SUNITINIB; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; DEGRADATION; DRUG CONJUGATION; DRUG DELIVERY DEVICE; DRUG FORMULATION; DRUG RELEASE; ENDOCYTOSIS; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; LYSOSOME; NANOMEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ANTIBODIES, IMMOBILIZED; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HEAD AND NECK NEOPLASMS; HUMANS; NANOPARTICLES; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SERUM ALBUMIN;

EID: 84870666685     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.11.007     Document Type: Article

References (48)

1. A. Abu Lila, T. Ishida, and H. Kiwada Targeting anticancer drugs to tumor vasculature using cationic liposomes Pharm. Res. 27 2010 1171 1183
2. F. Yang, C. Jin, Y. Jiang, J. Li, Y. Di, Q. Ni, and D. Fu Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside Cancer Treat. Rev. 37 2011 633 642
3. S. Parveen, and S.K. Sahoo Polymeric nanoparticles for cancer therapy J. Drug Target. 16 2008 108 123
4. U. Kedar, P. Phutane, S. Shidhaye, and V. Kadam Advances in polymeric micelles for drug delivery and tumor targeting Nanomedicine: NBM 6 2010 714 729
5. S. Dreis, F. Rothweiler, M. Michaelis, J. Cinatl Jr., J. Kreuter, and K. Langer Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles Int. J. Pharm. 341 2007 207 214
6. H. Jeong, M. Huh, S. Lee, H. Koo, I. Kwon, S. Jeong, and K. Kim Photosensitizer-conjugate human serum albumin nanoparticles for effective photodynamic therapy Theranostics 6 2011 230 239
7. S. Rhaese, H. von Briesen, H. Rübsamen-Waigmann, J. Kreuter, and K. Langer Human serum albumin-polyethylenimine nanoparticles for gene delivery J. Control. Release 92 2003 199 208
8. A.P. Retnakumari, P.L. Hanumanthu, G.L. Malarvizhi, R. Prabhu, N. Sidharthan, M.V. Thampi, D. Menon, U. Mony, K. Menon, P. Keechilat, S. Nair, and M. Koyakutty Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia Mol. Pharm. 2012 10.1021/mp300172e
9. K. Ulbrich, M. Michaelis, F. Rothweiler, T. Knobloch, P. Sithisarn, J. Cinatl, and J. Kreuter Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells Int. J. Pharm. 406 2011 128 134
10. F. Kratz Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J. Control. Release 132 2008 171 183
11. F. Petrelli, K. Borgonovo, and S. Barni Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel Expert. Opin. Pharmacother. 11 2010 1413 1432
12. F. Kratz, and B. Elsadek Clinical impact of serum proteins on drug delivery J. Control. Release 161 2012 429 445
13. K. Löw, M. Wacker, S. Wagner, K. Langer, and H. von Briesen Targeted human serum albumin nanoparticles for specific uptake in EGFR-expressing colon carcinoma cells Nanomedicine: NBM. 7 2011 454 463
14. M. Anhorn, S. Wagner, J. Kreuter, K. Langer, and H. von Briesen Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles Bioconjug. Chem. 19 2008 2321 2331
15. I. Steinhauser, B. Spänkuch, K. Strebhardt, and K. Langer Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells Biomaterials 27 2006 4975 4983
16. I.M. Steinhauser, K. Langer, K.M. Strebhardt, and B. Spänkuch Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation Biomaterials 29 2008 4022 4028
17. H. Wartlick, K. Michaelis, S. Balthasar, K. Strebhardt, J. Kreuter, and K. Langer Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells J. Drug Target. 12 2004 461 471
18. S. Wagner, F. Rothweiler, M.G. Anhorn, D. Sauer, I. Riemann, E.C. Weiss, A. Katsen-Globa, M. Michaelis, J. Cinatl Jr., D. Schwartz, J. Kreuter, H. von Briesen, and K. Langer Enhanced drug targeting by attachment of an anti αv integrin antibody to doxorubicin loaded human serum albumin nanoparticles Biomaterials 31 2010 2388 2398
19. N. Dinauer, S. Balthasar, C. Weber, J. Kreuter, K. Langer, and H. von Briesen Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes Biomaterials 26 2005 5898 5906
20. L. Zhang, S. Hou, S. Mao, D. Wei, X. Song, and Y. Lu Uptake of folate-conjugated albumin nanoparticles to the SKOV3 cells Int. J. Pharm. 287 2004 155 162
21. D. Zhao, X. Zhao, Y. Zu, J. Li, Y. Zhang, R. Jiang, and Z. Zhang Preparation, characterization and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles Int. J. Nanomedicine 20 2010 669 677
22. Q. Li, C. Liu, X. Zhao, Y. Zu, Y. Wang, B. Zhang, D. Zhao, Q. Zhao, L. Su, Y. Gao, and B. Sun Preparation, characterization and targeting of micronized 10-hydroxycamptothecin-loaded folate-conjugated human serum albumin nanoparticles to cancer cells Int. J. Nanomedicine 6 2011 397 405
23. J. Kreuter, T. Hekmatara, S. Dreis, T. Vogel, S. Gelperina, and K. Langer Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain J. Control. Release 118 2007 54 58
24. P.K. Dubey, D. Singodia, R.K. Verma, and S.P. Vyas RGD modified albumin nanospheres for tumour vasculature targeting J. Pharm. Pharmacol. 63 2011 33 40
25. X. Qu, C. Yang, J. Zhang, N. Ding, Y. Lu, L. Huang, and G. Xiang In vitro evaluation of a folate-bovine serum albumin-doxorubicin conjugate J. Drug Target. 18 2010 351 361
26. S. Muyldermans, and M. Lauwereys Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies J. Mol. Recognit. 12 1999 131 140
27. V. Joosten, M.S. Roelofs, N. van den Dries, T. Goosen, C.T. Verrips, C.A.M.J.J. van den Hondel, and B.C. Lokman Production of bifunctional proteins by Aspergillus awamori: llama variable heavy chain antibody fragment (VHH) R9 coupled to Arthromyces ramosus peroxidase (ARP) J. Biotechnol. 120 2005 347 359
28. P.A. Barthelemy, H. Raab, B.A. Appleton, C.J. Bond, P. Wu, C. Wiesmann, and S.S. Sidhu Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains J. Biol. Chem. 283 2008 3639 3654
29. I. Vaneycken, J. Govaert, C. Vincke, V. Caveliers, T. Lahoutte, P. De Baetselier, G. Raes, A. Bossuyt, S. Muyldermans, and N. Devoogdt In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/Micro-CT J. Nucl. Med. 51 2010 1099 1106
30. A.M. Eisenbeis, and S.J. Grau Monoclonal antibodies and Fc fragments for treating solid tumors Biologics 6 2012 13 20
31. R. Roovers, P. Henderikx, W. Helfrich, E. van der Linden, A. Reurs, A. de Bruïne, J. Arends, L. de Leij, and H. Hoogenboom High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting Br. J. Cancer 78 1998 1407 1416
32. F. Rahbarizadeh, D. Ahmadvand, and Z. Sharifzadeh Nanobody; an old concept and new vehicle for immunotargeting Immunol. Invest. 40 2011 299 338
33. S. Harmsen, M.E.M. Dolman, Z. Nemes, M. Lacombe, B. Szokol, J. Pató, G. Kéri, L. Orfi, G. Storm, W.E. Hennink, and R.J. Kok Development of a cell-selective and intrinsically active multikinase inhibitor bioconjugate Bioconjug. Chem. 22 2011 540 545
34. D. Berz, and H. Wanebo Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors J. Surg. Oncol. 103 2011 574 586
35. K. Temming, M. Lacombe, P. van der Hoeven, J. Prakash, T. Gonzalo, E. Dijkers, L. Orfi, G. Kéri, K. Poelstra, G. Molema, and R.J. Kok Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology Bioconjug. Chem. 17 2006 1246 1255
36. K. Langer, S. Balthasar, V. Vogel, N. Dinauer, H. von Briesen, and D. Schubert Optimization of the preparation process for human serum albumin (HSA) nanoparticles Int. J. Pharm. 257 2003 169 180
37. M.M. Fretz, M.E.M. Dolman, M. Lacombe, J. Prakash, T.Q. Nguyen, R. Goldschmeding, J. Pato, G. Storm, W.E. Hennink, and R.J. Kok Intervention in growth factor activated signaling pathways by renally targeted kinase inhibitors J. Control. Release 132 2008 200 207
38. S. Oliveira, R.M. Schiffelers, J. van der Veeken, R. van der Meel, R. Vongpromek, P.M.P. van Bergen en Henegouwen, G. Storm, and R.C. Roovers Downregulation of EGFR by a novel multivalent nanobody-liposome platform J. Control. Release 145 2010 165 175
39. S. Oliveira, R. Cohen, M. Stigter-van Walsum, G.A. van Dongen, S.G. Elias, P.J. van Diest, W. Mali, and P.M.P. van Bergen en Henegouwen A novel method to quantify IRDye800CW fluorescent antibody probes ex vivo in tissue distribution studies EJNMMI Research 2 2012 10.1186/2191-219X-2-50
40. A.O. Elzoghby, W.M. Samy, and N.A. Elgindy Albumin-based nanoparticles as potential controlled release drug delivery systems J. Control. Release 157 2012 168 182
41. J. Prakash, M. Sandovici, V. Saluja, M. Lacombe, R.Q.J. Schaapveld, M.H. de Borst, H. van Goor, R.H. Henning, J.H. Proost, F. Moolenaar, G. Këri, D.K.F. Meijer, K. Poelstra, and R.J. Kok Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4-fluorophenyl)-2-(4- hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular cells: a novel strategy to treat renal fibrosis JPET 319 2006 8 19
42. K. Langer, M.G. Anhorn, I. Steinhauser, S. Dreis, D. Celebi, N. Schrickel, S. Faust, and V. Vogel Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation Int. J. Pharm. 347 2008 109 117
43. A. Sorkin, and L.K. Goh Endocytosis and intracellular trafficking of ErbBs Exp. Cell Res. 314 2008 3093 3106
44. E. Boucrot, S. Saffarian, R. Massol, T. Kirchhausen, and M. Ehrlich Role of lipids and actin in the formation of clathrin-coated pits Exp. Cell Res. 312 2006 4036 4048
45. C. Antonescu, G. Danuser, and S. Schmid Phosphatidic acid plays a regulatory role in clathrin-mediated endocytosis Mol. Biol. Cell 21 2010 2944 2952
46. J.L. Ambroso, and C. Harris Chloroquine accumulation and alterations of proteolysis and pinocytosis in the rat conceptus in vitro Biochem. Pharmacol. 47 1994 679 688
47. M. Talelli, M. Iman, A.K. Varkouhi, C.J.F. Rijcken, R.M. Schiffelers, T. Etrych, K. Ulbrich, C.F. van Nostrum, T. Lammers, G. Storm, and W.E. Hennink Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin Biomaterials 31 2010 7797 7804
48. R. van der Meel, S. Oliveira, I. Altintas, R. Haselberg, J. van der Veeken, R.C. Roovers, P.M.P. van Bergen en Henegouwen, G. Storm, W.E. Hennink, R.M. Schiffelers, and R.J. Kok Tumor-targeted nanobullets: anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment J. Control. Release 159 2012 281 289